Table 1.
Cancera,b | Sample size | Full (# mutations ≥ 6) |
FoundationOne (# mutations ≥ 1) |
PanCan (# mutations ≥ 1) |
TrueSeq (# mutations ≥1) |
---|---|---|---|---|---|
BLCA | 99 | 99 (100%) | 97(98%) | 95 (96%) | 84 (85%) |
BRCA | 887 | 849 (96%) | 661 (75%) | 647 (73%) | 528 (60%) |
CRC | 233 | 233 (100%) | 227 (97%) | 226 (97%) | 219 (94%) |
ESO | 140 | 140 (100%) | 133 (95%) | 125 (89%) | 112 (80%) |
GBM | 291 | 288 (99%) | 247 (85%) | 237 (81%) | 199 (68%) |
HNSC | 384 | 372 (97%) | 357 (93%) | 347 (90%) | 303 (79%) |
KIRC | 417 | 414 (99%) | 328 (79%) | 310 (74%) | 220 (53%) |
LUAD | 398 | 391 (98%) | 372 (93%) | 359 (90%) | 322 (81%) |
LUSC | 176 | 176 (100%) | 176 (100%) | 175 (99%) | 158 (90%) |
MEL | 118 | 118 (100%) | 117 (99%) | 113 (96%) | 112 (95%) |
MM | 204 | 200 (98%) | 157 (77%) | 146 (72%) | 121(59%) |
OV | 316 | 313 (99%) | 276 (87%) | 281 (89%) | 238 (75%) |
UCEC | 247 | 247 (100%) | 245 (%99) | 242 (98%) | 229 (93%) |
Total | 4143 | 4008 |
aBLCA-Bladder urothelial carcinoma; BRCA-Breast invasive carcinoma; CRC-Colorectal carcinoma; ESO-Esophageal adenocarcinoma; GBM-Glioblastoma multiforme; HNSC-Head and neck squamous cell carcinoma; KIRC-Kidney renal clear cell carcinoma; LUAD-Lung adenocarcinoma; LUSC-Lung squamous cell carcinoma; MEL-Melanoma; MM-Multiple myeloma; OV-Ovarian serous cystadenocarcinoma; UCEC-Uterine corpus endometrial carcinoma
bCancer types with survival data: BLCA, BRCA, CRC, ESO, GBM, HNSC, KIRC, LUAD, LUSC, OV,UCEC.